Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate

DOI: 10.5306/wjco.v8.i2.100

Keywords: Axitinib, Everolimus, Cabozantinib, Kidney cancer, Nivolumab, Renal cell, Sequence, Second line, Sorafenib, Tumor-growth rate

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text